Atmo Biosciences selected into ANDHealth+ commercialization program to help scale its products nationally and internationally
August 25, 2023.
Atmo Biosciences is one of only five businesses accepted into the market-leading ANDHealth+ commercialization program, which helps digital health companies to scale their products nationally and internationally.
The program will provide the companies with up to A$3.75 million in non-dilutive funding, alongside hands-on support by a world-class network of experts to help them to scale their businesses.
ANDHealth+ is the flagship program of leading Australian health technology commercialisation group ANDHealth. Funded by the Medical Research Future Fund (MRFF), ANDHealth+ is the leading dedicated digital health commercialisation support program in Australia.
Atmo Biosciences was previously chosen as an inaugural member of the ANDHealth+ digital health commercialization program in 2017.
Atmo Biosciences CEO Mal Hebblewhite said Atmo was delighted to once again be selected as an ANDHealth+ cohort member.
“This program will enable Atmo to advance our health economics and reimbursement plan whilst we prepare for US market entry. Atmo is conducting a multi-site pivotal study to support a FDA 510(k) submission next year. Reimbursement will play a key role in driving clinical adoption. We look forward to working with the ANDHealth team on this initiative,” Mr. Hebblewhite said.
The ANDHealth+ participants were selected via a rigorous application process which leveraged the knowledge, skills and experience of industry leaders from multiple related sectors as well as ANDHealth’s International Investment Advisory Committee.
ANDHealth CEO and Managing Director, Bronwyn Le Grice said: “ANDHealth+ is a highly competitive program and the selection panel has been impressed by the continual improvement in the quality of applications over time.”
“These five exceptional companies will receive highly targeted expert advice and mentoring from international industry leaders, specialized commercialization expertise, and significant non-dilutive investment to generate the clinical and commercial evidence required to scale their digital health products and services nationally and internationally,” Ms. Le Grice said.